Literature DB >> 32240382

Ventral hernia repair by totally extraperitoneal approach (VTEP): technique description and feasibility study.

Philippe Ngo1, Jean-Pierre Cossa1, Claude Largenton2, Hubert Johanet1, Sylvie Gueroult1, Edouard Pélissier3.   

Abstract

BACKGROUND: The repair of ventral hernias by intra-peritoneal patch (IPOM) involves a risk of pain due to stapling as well as intestinal adhesions. Extraperitoneal placement of the patch without fixation can prevent these drawbacks. Techniques of endoscopic preperitoneal repair were previously described by others. The aim of this article is to describe our technique and to evaluate the feasibility and short-term results.
METHODS: The totally endoscopic technique consists of dividing the median aponeurotic structures, while preserving the proper linea alba, to create a unique retro-muscular space, in which the patch is deployed without any fixation. Hundred twelve consecutive patients were operated on for ventral hernias (82 umbilical, 20 epigastric, 10 combined). Perioperative data including duration of operation, technical problems, conversions and complications, as well as postoperative pain, time to resume daily activities and time off work were prospectively assessed.
RESULTS: 98 (87.5%) patients were operated in ambulatory surgery, and 14 (12.5%) in overnight stay. The mean sizes of the hernia and the patch were 9 (1-50) cm2 and 225 (50-500) cm2, respectively. The mean operation duration was 75 (30-270) min. The peritoneum was opened in 43 (38.4%) cases and closed by suture in 41 instances. There were 5 (4.5%) conversions to IPOM and 4 (3.6%) complications (1 seroma, 1 urine retention, 1 transitory ileus, and 1 intestinal obstruction) which were reoperated. The mean VAS value of postoperative pain was 2.45 (0-8), pain was scored 0 by 17 (15%) patients. The mean times to resume daily activity and work were 4 (1-15) days and 11.5 (1-30) days, respectively.
CONCLUSION: Our results suggest that VTEP is safely feasible by surgeons skilled in laparoscopy, and might contribute to minimize pain, though this must be established by comparative studies.

Entities:  

Keywords:  Endoscopic hernia repair; Epigastric hernia; Extraperitoneal hernia repair; Umbilical hernia; VTEP; Ventral hernias

Mesh:

Year:  2020        PMID: 32240382     DOI: 10.1007/s00464-020-07519-2

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  1 in total

1.  Severity and incidence of complications assessed by the Clavien-Dindo classification following robotic and laparoscopic gastrectomy for advanced gastric cancer: a retrospective and propensity score-matched study.

Authors:  Wen-Jie Wang; Hong-Tao Li; Jian-Ping Yu; Lin Su; Chang-An Guo; Peng Chen; Long Yan; Kun Li; You-Wei Ma; Ling Wang; Wei Hu; Yu-Min Li; Hong-Bin Liu
Journal:  Surg Endosc       Date:  2018-12-17       Impact factor: 4.584

  1 in total
  4 in total

1.  Endoscopic transversus abdominis release in the treatment of midline incisional hernias: a prospective single-center observational study on 100 patients.

Authors:  V Burdakov; A Zverev; N Matveev
Journal:  Hernia       Date:  2022-07-20       Impact factor: 2.920

2.  Comparison of outcomes in rectus abdominis diastasis repair-which data do we need in a hernia registry?

Authors:  F Köckerling; R Lorenz; B Stechemesser; J Conze; A Kuthe; W Reinpold; H Niebuhr; B Lammers; K Zarras; R Fortelny; F Mayer; H Hoffmann; J F Kukleta; D Weyhe
Journal:  Hernia       Date:  2021-07-28       Impact factor: 4.739

3.  Stapled VTEP (sVTEP), diastasis and the "swollen abdomen".

Authors:  Jean-Pierre Cossa; Philippe Ngo; Édouard Pélissier
Journal:  Surg Endosc       Date:  2021-07-23       Impact factor: 4.584

4.  Short-term outcomes of minimally invasive retromuscular ventral hernia repair using an enhanced view totally extraperitoneal (eTEP) approach: systematic review and meta-analysis.

Authors:  D Aliseda; C Sanchez-Justicia; G Zozaya; J Lujan; A Almeida; N Blanco; P Martí-Cruchaga; F Rotellar
Journal:  Hernia       Date:  2022-01-19       Impact factor: 4.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.